StockNews.AISignal intelligence
Q32 Bio Inc. · NASDAQ · Healthcare
Browse public QTTB signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Phase IIb data show meaningful hair regrowth in severe alopecia areata with a favorable safety profile. In Part B, mean SALT reduction at Week 36 was 35.3%, with 40% SALT-20 and 44% SALT-30/50 responses, including severe and very severe cases. The extension study supports maintenance dosing, and the company targets a registration-directed program in 1H 2027, prompting a sharp premarket rally.
View signal analysisQTTB shares surged 171% to $5.91 after significant deal. QTTB sold ADX-097 for $12 million plus up to $592 million. U.S. stocks fell broadly; only energy sectors rose slightly. S&P Global manufacturing PMI revised higher, but still lower than October. Negative market sentiment may impact stocks in the short-term.
View signal analysisQ32 Bio sold ADX-097 to Akebia Therapeutics for $12 million. The deal could yield up to $592 million in future milestones. Q32 Bio stocks surged by 115.07% following the announcement. ADX-097 is aimed at treating various diseases linked to C3d deposition. Cash reserves expected to fund operations through late 2027.
View signal analysisQ32 Bio's bempikibart failed primary endpoint in alopecia trial. Post-hoc analysis showed promising hair regrowth results. No serious adverse events were reported in the trial. Company plans to expand trial with more patient enrollment. Focus shifts from ANCA-AAV to alopecia and atopic dermatitis trials.
View signal analysis